ReviewFrontiers in nutrition2021
How Early-Life Gut Microbiota Alteration Sets Trajectories for Health and Inflammatory Bowel Disease?
Review in Frontiers in nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Probiotic improves respiratory and gastrointestinal health, immune homeostasis, and gut microbiota composition in infants: a randomized controlled trial.Frontiers in nutrition · 2026Trial
- Novel insights into how gestational diet affects maternal-infant microbiota: a cross-sectional causal mediation analysis at one month postpartum.European journal of nutrition · 2026Observational
- Preoperative gut microbial and metabolic signatures associated with postoperative Hirschsprung-associated enterocolitis in short-segment Hirschsprung disease.Frontiers in microbiology · 2026Article
- ProbioticAntioxidants (Basel, Switzerland) · 2025Article
- Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm.Probiotics and antimicrobial proteins · 2025Review
- Seven hundred and ninety-seven metagenome-assembled genomes from the goat rumen during early life.Scientific data · 2024Article
- Early-life gut bacterial community structure predicts disease risk and athletic performance in horses bred for racing.Scientific reports · 2024Article
- Mouse diet and vendor impact microbiome perturbation and recovery from early-life pulses of amoxicillin.Frontiers in microbiomes · 2024Article
- An Overview of the Influence of Breastfeeding on the Development of Inflammatory Bowel Disease.Nutrients · 2023Review
- Research progress on the relationship between Paneth cells-susceptibility genes, intestinal microecology and inflammatory bowel disease.World journal of clinical cases · 2023Review
- Exploring the Early-Life Microbiome and Future Risk of Inflammatory Bowel Disease.Gastroenterology & hepatology · 2023Article
- TNF ΔARE Pigs: A Translational Crohn's Disease Model.Journal of Crohn's & colitis · 2023Article
- Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases.The Journal of nutritional biochemistry · 2023Review
- The role of potential probiotic strainsFrontiers in microbiology · 2023Review
- Cross talk between the gut microbiome and host immune response in ulcerative colitis: nonpharmacological strategies to improve homeostasis.American journal of physiology. Gastrointestinal and liver physiology · 2022Review
- Article
- Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models.International journal of molecular sciences · 2022Review
- Understanding exposures and latent disease risk within the National Institute of Environmental Health Sciences Superfund Research Program.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Effect of the Microbiome on Intestinal Innate Immune Development in Early Life and the Potential Strategy of Early Intervention.Frontiers in immunology · 2022Review
- Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy.Frontiers in immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a recurrent chronic inflammatory condition of the intestine without any efficient therapeutic regimens. Gut microbiota, which plays an instrumental role in the development and maturation of the immune system, has been implicated in the pathogenesis of IBD. Emerging evidence has established that early-life events particularly maternal influences and antibiotic treatment are strongly correlated with the health or susceptibility to disease of an individual in later life. Thus, it is proposed that there is a critical period in infancy, during which the environmental exposures bestow a long-term pathophysiological imprint. This notion sheds new light on the development of novel approaches for the treatment, i.e., early interventions, more precisely, the prevention of many uncurable chronic inflammatory diseases like IBD. In this review, we have integrated current evidence to describe the feasibility of the "able-to-be-regulated microbiota," summarized the underlying mechanisms of the "microbiota-driven immune system education," explored the optimal intervention time window, and discussed the potential of designing early-probiotic treatment as a new prevention strategy for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.